Ginkgo Bioworks
This microcap biotech has strong upside potential for investors looking for ideas in the space. Ginkgo Bioworks Holdings Inc. (NYSE: DNA) develops a platform used to program cells to enable biological production of products, such as novel therapeutics, food ingredients and chemicals derived from petroleum.
The company serves various end markets, including specialty chemicals, agriculture, food, consumer products and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences to advance treatments for orphan and rare diseases.
This week, the company announced the launch of Ginkgo Enzyme Services, which is powered by ultra-high throughput screening and machine learning-guided protein design, as well as optimized proprietary bacterial and fungal host strains. Ginkgo Enzyme Services solves challenges for R&D teams developing enzymes, from discovery of novel enzyme activity through optimization of enzyme function and large-scale manufacturing.
Raymond James has a $14.50 target price on Ginkgo Bioworks stock. The consensus target is just $5.82. The stock traded on Friday at $1.85. Hitting the Raymond James target would be a 690% or so gain.
Holley
Do-it-yourself car enthusiasts know this old-school company well. Holley Inc. (NYSE: HLLY) designs, manufactures and markets automotive aftermarket products for car and truck enthusiasts in the United States, Canada, Europe and China.
The company’s products include carburetors, fuel pumps, fuel injection systems, nitrous oxide injection systems, superchargers, exhaust headers, mufflers, distributors, ignition components, engine tuners, automotive performance plumbing products and exhaust products, as well as shifters, converters, transmission kits, transmissions, tuners and automotive software. It also offers wheels, chassis and suspension products, helmets, head and neck restraints, seat belts, firesuits, and electronic control and monitoring systems.
The company sells its products under the Holley, Holley EFI, APR, MSD, Flowmaster, Powerteq, Accel and Simpson brands to retailers directly, as well as through distributors and online channels.
Earlier this year the stock was added to the Russell 2000, which is a huge advantage as index funds that replicate the index in its entirety have to buy the shares.
The $9 Raymond James target price compares with the $6 consensus target. Shares traded on Friday at $2.75, so hitting the Raymond James target would be a gain of about 235%.
Sponsored: Find a Qualified Financial Advisor
Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.